Column Group IV GP, LP

CIK: 0001796356

Transaction Breakdown

Open Market Buys (P)4 (36.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)7 (63.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EIKN

Eikon Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (11 total)

EIKN
Eikon Therapeutics, Inc.
Sep 3, 2026
Purchase(P)
Indirect
89.2K shares at avg. $11.56$1.0M
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
1.4M shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
110.9K shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
44.2K shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
47.9K shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
1.3M shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
688.3K shares-
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Purchase(P)
Indirect
1.4M shares at avg. $18.00$25.9M
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Purchase(P)
Indirect
49.6K shares at avg. $18.00$892K
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Purchase(P)
Indirect
630.9K shares at avg. $18.00$11.4M
EIKN
Eikon Therapeutics, Inc.
Feb 6, 2026
Conversion(C)
Indirect
3.8K shares-

		Type	Shares	Price		Ownership
Sep 3, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	89,200	$11.56	$1,031,045	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	1,403,568	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	110,928	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	44,249	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	47,898	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	1,296,629	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	688,283	-	$0	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	1,437,323	$18.00	$25,871,814	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	49,556	$18.00	$892,008	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Purchase(P)	630,881	$18.00	$11,355,858	Indirect
Feb 6, 2026	EIKN Eikon Therapeutics, Inc.	Conversion(C)	3,785	-	$0	Indirect

1-11 of 11 transactions

About Column Group IV GP, LP

Column Group IV GP, LP (SEC CIK 0001796356) files insider reports with the SEC as 10% Owner of Eikon Therapeutics, Inc. (EIKN).

Signal8 holds 3 ownership filings by Column Group IV GP, LP (1 Form 3, 2 Form 4), filed between Feb 4, 2026 and Sep 8, 2026. Those filings report 11 transactions, from Feb 6, 2026 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Column Group IV GP, LP's filings is in SAN FRANCISCO, CA.

Recent filings by Column Group IV GP, LP

Sep 3, 2026: Open-market purchase of EIKN shares (Form 4, code P).
Feb 6, 2026: Conversions of EIKN shares (6 lines, Form 4, code C).
Feb 6, 2026: Open-market purchases of EIKN shares (3 lines, Form 4, code P).
Feb 6, 2026: Conversion of EIKN shares (Form 4, code C).

Other insiders filing for Eikon Therapeutics, Inc. (EIKN)

Francisco Ma. Fatima, Director
Klobuchar Michael A, Chief Operating Officer
Huffines Robert Luther, Director
FRAZIER KENNETH C, Director
PERLMUTTER ROGER M
Thorner Benjamin Bruno

How to read Form 4 transaction codes